Key Takeaways
- Custom Synthesis engines firing, but Generics pricing masks it: Two large-scale projects are now in full production and GLP-1 building blocks represent a major new growth engine, yet gross margin fell ~400-500 bps QoQ as generic API pricing pressure and high-cost inventory consumed the gains.
- GLP-1 opportunity is real and large: Management framed the specialized protected amino acid supply as potentially "bigger than a single growth engine," with meaningful value visible toward FY25 and very large volumes thereafter.
- Pricing pressure is cyclical, not structural: The squeeze in large-volume generics comes from existing players destocking, not new entrants; management has seen 2-3 such cycles in 10 years and expects it to settle in coming quarters.
- Unit 3 greenfield on track for late FY25 production start: The 200-acre Phase I project will free up Units 1 and 2 for new Custom Synthesis and Generic opportunities, though management declined to quantify the coming operational cost step-up.
- What to watch next quarter: Whether generic pricing stabilizes as management expects, the revenue contribution from the two newly commercialized Custom Synthesis projects, and any further color on GLP-1 qualification timelines.
Custom Synthesis: The Growth Engine Firing
- Two big pharma projects now at full scale: Both large-volume custom synthesis projects have moved to full production capacity, with results expected to flow into revenue over coming quarters.
- Growth is diversified, not single-customer: Custom Synthesis growth is distributed across several therapeutic segments, not tied to one company or product, reducing concentration risk.
- Customer base insulated from biotech funding stress: Divi's works with big pharma on their internal pipelines or pipelines acquired from small companies, so it sees no slowdown from the start-up funding crunch and continues to see a number of opportunities.
- Contrast media backward integration deepens the moat: Divi's is the most backward-integrated company in contrast media, manufacturing from basic Iodine and Isophthalic acid; it already supplies Iopamidol and Iohexol for the generic market and is entering at least two more Iodine-based compounds.
- Gadolinium-based contrast media in final process stage: The product is in final stages of process completion, with customer qualifications and samples to follow; supplies are expected more toward FY25 than this fiscal.
Dr. Murali K Divi: "The Custom Synthesis growth is not just one company or one product, it is distributed over several therapeutic segments."
GLP-1: The Next Growth Engine
- A building-block opportunity few can serve at scale: Outside China, few companies can supply the specialized protected amino acids required for GLP-1 peptide synthesis at hundreds of tons; Divi's is one of them, with chemistry capabilities and existing capacity already in place.
- Sized as a multi-product, multi-year wave: Management sees the opportunity as potentially bigger than a single growth engine because several products are emerging in the GLP-1 agonist segment, not just one.
- Timeline: light in FY25, large volumes after: Once approvals and qualifications complete, some value will be visible toward FY25, with much bigger numbers following.
- Capacity already exists: Management stated all reagents and building blocks can be produced in existing facilities, deflecting a question about specific capacity investments.
Dr. Murali K Divi: "The opportunity is like another growth engine, you are right. It's not a small opportunity. It can be even bigger than a single growth engine."
Generic APIs: Volume Healthy, Pricing Weak
- Volume is there, pricing is not: Good volume trends in generic APIs are masked by lower pricing, so revenue is only moderately higher than last year.
- The pressure is cyclical destocking, not new competition: Existing players are doing stock play and disposing of inventory, a phenomenon management has seen 2-3 times over the last decade; it expects pricing to settle in coming quarters.
- Newer generics are holding up: Pricing pressure is concentrated in large-volume legacy generics; recently introduced products are not seeing the same squeeze.
- Sartans are a top-10 contributor: Sartans as a family rank among Divi's top 10 product segments by both opportunity and existing revenue.
- Inventory destocking cycles run under two years: Different products cycle at different times, but the pattern is consistent: mid-to-low players build inventory, cannot hold, dispose at lower prices, stocks deplete, shortages emerge, prices rise, then settle.
Nilima Divi: "The volume is there. It's just that the pricing is lower, so that's when you're seeing the revenue is moderately more than what it was last year."
Margins: Hit by Generics Pricing and One-off Costs
- Gross margin down 400-500 bps sequentially: The deterioration came despite strong Custom Synthesis performance, driven by generic API pricing pressure and some high-cost stock toward the end of consumption.
- INR 20 crores Molnupiravir inventory written off: The write-off was for materials left over from the COVID drug, a one-time clean-up.
- Other expenses rose on modernization spend: Repair and maintenance expenditure increased due to upgradation at Unit 1 and Unit 2.
- Management expects margin improvement ahead: Stated "going forward, should be doing better on margins," though no quantified target was given.
- Unit 3 will add operating costs: Management confirmed operational expenses will rise with Unit 3 setup, directly proportional to volume loaded quarter-on-quarter, but declined to provide a ballpark number.
Strategic Positioning & Capacity
- Unit 3 Phase I on track for late FY25: The 200-acre greenfield project is progressing well, with production activities planned to commence toward the end of Q1 FY25; it will free up Units 1 and 2 for new Custom Synthesis and Generic opportunities.
- US FDA Commissioner visit signals regulatory standing: The Commissioner toured Divi's facilities with 12 officials, giving them a detailed picture of the API industry's scale and quality systems; management noted "the world knows that he has visited us and carried some good impression."
- India positioned as partner of choice: With large capacities available in India and requirements in the US and Europe, management sees India as a partner of choice for innovative molecule supply chains, with China Plus One playing out in APIs and intermediates.
- Custom Synthesis to Generic ratio is fluid: Management would like to maintain 50-50, but it shifts 60-40 or 40-60 year-on-year depending on business mix, which is not fully in their control.
- Recently filed DMFs contribute beyond FY25: New DMF filings are expected to support growth after financial year 2025.
Dr. Murali K Divi: "For a stable player like ours, it should not matter. We don't disappear when the price comes down and we don't appear when the price increases by 20%."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Unit 3 Phase I production start | Commence production activities | End of Q1 FY25 |
| Generic pricing stabilization | Pricing pressure in large-volume generics to settle | Coming quarters |
| GLP-1 building blocks revenue | Some value visible, then very large volumes | Light toward FY25; large volumes after qualifications |
| Gadolinium-based contrast media supplies | Customer qualifications and samples first | More toward FY25 than this fiscal |
| Custom Synthesis revenue visibility | More clarity expected | From Q3 FY24 |
| DMF-driven growth contribution | Recently filed DMFs to contribute | Beyond FY25 |
| Inventory destocking cycle duration | Not more than 2 years per cycle | Per historical pattern |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Consolidated total income | ₹1,995 cr, vs ₹1,935 cr in Q2 FY23 and ₹1,859 cr in Q1 FY24 |
| Ex-Covid portfolio growth | Double-digit YoY for the quarter and half year |
| Constant currency growth | Negative 1% for the quarter |
| Profit before tax | ₹469 cr for the quarter |
| Profit after tax | ₹348 cr for the quarter |
| Material consumption | 42% of revenue, higher due to product mix and pricing pressure |
| Forex gain | ₹11 cr, vs ₹31 cr gain in Q2 FY23 |
| Exports share | 87% of total income |
| Exports to Europe and U.S. | 68% of total income |
| Generics to Custom Synthesis mix | 60:40 for the quarter |
| Nutraceutical business revenue | ₹205 cr for the quarter |
| Carotenoid products sales growth | ~15% increase this quarter |
| Inventory write-off | ₹20 cr, related to leftover COVID drug materials |
| Capital work in progress | ₹496 cr as of end September 2023, of which Kakinada project is ₹263 cr |
| Cash on books | ₹3,604 cr as of 30th September 2023 |
| Receivables | ₹1,858 cr as of 30th September 2023 |
| Inventories | ₹2,969 cr as of 30th September 2023 |